DEC 18, 2020 6:51 AM PST

Not Just THC and CBD: Study Investigates Potential of Minor Cannabinoids

WRITTEN BY: Angela Dowden

Cannabinoids are the natural compounds in the cannabis plant that interact with the body's endocannabinoid system. Despite largely hearing about CBD (cannabidiol) and THC (tetrahydrocannabinol) there are actually many more minor cannabinoids in the plant, but their impact on health has largely been undiscovered.

Now a new Canadian study from the Pharmacy and Nutrition unit at the University of Saskatchewan, Saskatoon has attempted to categorise and assign activities to some of these cannabinoids both in vitro and in vivo. For the in vitro part of the study the cannabinoids were tested at the CB1 and CB2 cannabinoid receptor sites of Chinese hamster ovary cells and for the in vivo part cannabinoids were administered to mice

The teams assessed the activity of 8 cannabinoids: these were THC and CBD as well as six minor cannabinoids, namely tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), and cannabichromene (CBC).

The results showed differential binding to CH1 and C2 along lines already reported:  all eight cannabinoids tested had some level of binding to CB1 but, other than for THC, this binding was weak. Most of the cannabinoids also bound to CB2, including THC, but  CBD bound poorly to this receptor.

In the mice, they found that THC, THCA, and THCV—but not CBD—reduced pain, while THC, CBD, THCA, THCV, and CBG all had a positive impact on anxiety.

The authors concluded THCA and THCV, which bound both CB1 and CB2, may be able to reduce pain, inflammation, and anxiety when either is used in the absence of other cannabinoids. This finding is significant since there is a growing interest in the clinical applications of single-cannabinoid preparations.

However the authors say that further study is warranted to see what other receptors other than just CB1 and CB2 might be important. They also commented that cannabis is a special case compared with most pharmaceuticals that have single active ingredients.

“Cannabis products contain many phytomolecules that are co-administered when Cannabis is consumed. This study represents an initial foray into potential between- and among-biomolecule interactions that can be built upon gradually. Pharmacology is a reductionist approach to biochemical interactions that cannot always model the complex interactions occurring in nature”. 

The National Institute for Health is already investigating various minor cannabinoids and terpenes in cannabis for their pain-relieving benefits; it was announced in September 2019.

 

Sources: Nature, Marijuana Business Daily

 

About the Author
  • I'm a journalist and author with many year's experience of writing for both a consumer and professional audience, mostly on nutrition, health and medical prescribing. My background is food science and I'm a registered nutritionist.
You May Also Like
MAY 29, 2021
Health & Medicine
No Uptick in Students of High School Age Using Cannabis
MAY 29, 2021
No Uptick in Students of High School Age Using Cannabis
It’s a startling statistic: In 2019, about 22 percent of students in grades 9–12 reported that illegal drugs ...
MAY 30, 2021
Genetics & Genomics
Massive Genetic Study Reveals Risk Factors for Depression
MAY 30, 2021
Massive Genetic Study Reveals Risk Factors for Depression
It's estimated that 20% of Americans has experienced depression and that 4% of the global population is depressed. Genet ...
JUN 04, 2021
Clinical & Molecular DX
Tiny Bone Marrow Models Help Tailor Treatments for Platelet Disorder Patients
JUN 04, 2021
Tiny Bone Marrow Models Help Tailor Treatments for Platelet Disorder Patients
  Scientists have developed miniaturized 3-dimensional bone marrow models that could help physicians to predict whi ...
JUN 09, 2021
Genetics & Genomics
Going to Bed an Hour Earlier Cuts Depression Risk Significantly
JUN 09, 2021
Going to Bed an Hour Earlier Cuts Depression Risk Significantly
Could it be possible to reduce the risk of developing depression by 23% simply by waking up an hour earlier? That's what ...
JUN 11, 2021
Drug Discovery & Development
Laughing Gas Shows Promise in Rapid Relief of Treatment-Resistant Depression
JUN 11, 2021
Laughing Gas Shows Promise in Rapid Relief of Treatment-Resistant Depression
Researchers led by the University of Chicago Medicine and Washington University have found that low doses of laughing ga ...
JUN 11, 2021
Neuroscience
Excess Sugar in Children May be Linked to Attention Deficit Disorder
JUN 11, 2021
Excess Sugar in Children May be Linked to Attention Deficit Disorder
Researchers led by the Queensland University of Technology in Australia have found that children who consume excessive a ...
Loading Comments...